FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214747827> ?p ?o ?g. }

• W3214747827 abstract "Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of both lung cancer and head and neck squamous cell carcinoma demonstrating clear benefit over traditional chemotherapy alone in the metastatic setting. While the overwhelming majority of ICI trial participants have been White patients, results of these trials have been broadly applied to patients of all ethnic/racial backgrounds. It has, therefore, not been well defined if response to ICIs differs between ethnic/racial populations or socio-economic groups. We reviewed response to ICI of 208 patients with diagnoses of lung or head and neck cancers treated with ICI between 2015 and 2020 at one of three clinical pavilions associated with the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX. Two of these pavilions (Harris Health System and the Michael E. DeBakey Veterans Affairs Medical Center) serve large minority patient populations and provide equal access of care to patients regardless of means. Of the 208 patients, 175 had a diagnosis of lung cancer [non-small cell lung carcinoma (NSCLC) or small cell lung cancer (SCLC)] and 33 had a diagnosis of head and neck squamous cell carcinoma (HNSCC); 38% self-identified as Black, 45% as non-Hispanic White, and 18% as Hispanic. The objective response rate (ORR) was similar for lung cancer (31.4%) and HNSCC patients (27.3%) (p=0.894). Statistically, the ORR for Hispanic and Black patients did not differ compared to non-Hispanic White patients (H 23.7%, B 28.6%, W 35.5%; H vs. W p=0.189; B vs. W p=0.338). When considering patients treated with ICI monotherapy, the ORR for Hispanic patients dropped to 13.3% and was significantly lower than the ORR of the non-Hispanic White patients while the ORR of Black and non-Hispanic White patients remained about the same (B 29.3% and W 34.6%, H vs. W p=0.0285; B vs. W p=0.5131). Immune related adverse events (irAEs) were the lowest in the Hispanic population occurring in only 30% of patients compared to 50% of patients exhibiting irAEs in the Black and non-Hispanic white cohorts. ICIs demonstrate comparable anti-tumor effects in lung cancer (NSCLC + SCLC) and HNSCC during routine clinical practice regardless of race or ethnicity. The significantly lower ORR observed in our cohort for Hispanic patients, particularly when used as monotherapy, is an unexpected finding and will require additional study to identify potential biological and non-biological confounders which could contribute to reduced ICI effectiveness in this patient population." @default.
• W3214747827 created "2021-12-06" @default.
• W3214747827 creator A5010529228 @default.
• W3214747827 creator A5018430323 @default.
• W3214747827 creator A5020795619 @default.
• W3214747827 creator A5022436156 @default.
• W3214747827 creator A5042242807 @default.
• W3214747827 creator A5053809085 @default.
• W3214747827 creator A5057033324 @default.
• W3214747827 creator A5070971899 @default.
• W3214747827 creator A5076780072 @default.
• W3214747827 creator A5077423550 @default.
• W3214747827 creator A5089223773 @default.
• W3214747827 creator A5090773204 @default.
• W3214747827 date "2021-11-28" @default.
• W3214747827 modified "2023-09-27" @default.
• W3214747827 title "Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access" @default.
• W3214747827 cites W1736831658 @default.
• W3214747827 cites W1805776597 @default.
• W3214747827 cites W1982488143 @default.
• W3214747827 cites W2104347254 @default.
• W3214747827 cites W2147254169 @default.
• W3214747827 cites W2156353875 @default.
• W3214747827 cites W2164400197 @default.
• W3214747827 cites W2198093519 @default.
• W3214747827 cites W2218992589 @default.
• W3214747827 cites W2527905628 @default.
• W3214747827 cites W2529484692 @default.
• W3214747827 cites W2560453842 @default.
• W3214747827 cites W2567564314 @default.
• W3214747827 cites W2588278369 @default.
• W3214747827 cites W2774533844 @default.
• W3214747827 cites W2795186863 @default.
• W3214747827 cites W2796582438 @default.
• W3214747827 cites W2804649027 @default.
• W3214747827 cites W2805354595 @default.
• W3214747827 cites W2891457349 @default.
• W3214747827 cites W2892640821 @default.
• W3214747827 cites W2904996690 @default.
• W3214747827 cites W2917245118 @default.
• W3214747827 cites W2924745935 @default.
• W3214747827 cites W2953398117 @default.
• W3214747827 cites W2969031691 @default.
• W3214747827 cites W2970363737 @default.
• W3214747827 cites W2981565334 @default.
• W3214747827 cites W2986633517 @default.
• W3214747827 cites W3007921007 @default.
• W3214747827 cites W3016280944 @default.
• W3214747827 cites W3021491495 @default.
• W3214747827 cites W3022369650 @default.
• W3214747827 cites W3037051665 @default.
• W3214747827 cites W3041067437 @default.
• W3214747827 cites W3045387375 @default.
• W3214747827 cites W3045637110 @default.
• W3214747827 cites W3083775803 @default.
• W3214747827 cites W3092678161 @default.
• W3214747827 cites W3094478256 @default.
• W3214747827 cites W3107975240 @default.
• W3214747827 cites W3142613885 @default.
• W3214747827 doi "https://doi.org/10.1101/2021.11.26.21266821" @default.
• W3214747827 hasPublicationYear "2021" @default.
• W3214747827 type Work @default.
• W3214747827 sameAs 3214747827 @default.
• W3214747827 citedByCount "1" @default.
• W3214747827 countsByYear W32147478272022 @default.
• W3214747827 crossrefType "posted-content" @default.
• W3214747827 hasAuthorship W3214747827A5010529228 @default.
• W3214747827 hasAuthorship W3214747827A5018430323 @default.
• W3214747827 hasAuthorship W3214747827A5020795619 @default.
• W3214747827 hasAuthorship W3214747827A5022436156 @default.
• W3214747827 hasAuthorship W3214747827A5042242807 @default.
• W3214747827 hasAuthorship W3214747827A5053809085 @default.
• W3214747827 hasAuthorship W3214747827A5057033324 @default.
• W3214747827 hasAuthorship W3214747827A5070971899 @default.
• W3214747827 hasAuthorship W3214747827A5076780072 @default.
• W3214747827 hasAuthorship W3214747827A5077423550 @default.
• W3214747827 hasAuthorship W3214747827A5089223773 @default.
• W3214747827 hasAuthorship W3214747827A5090773204 @default.
• W3214747827 hasBestOaLocation W32147478271 @default.
• W3214747827 hasConcept C121608353 @default.
• W3214747827 hasConcept C126322002 @default.
• W3214747827 hasConcept C137403100 @default.
• W3214747827 hasConcept C143998085 @default.
• W3214747827 hasConcept C144024400 @default.
• W3214747827 hasConcept C19165224 @default.
• W3214747827 hasConcept C2775969662 @default.
• W3214747827 hasConcept C2776256026 @default.
• W3214747827 hasConcept C2776530083 @default.
• W3214747827 hasConcept C2776694085 @default.
• W3214747827 hasConcept C2776833033 @default.
• W3214747827 hasConcept C71924100 @default.
• W3214747827 hasConceptScore W3214747827C121608353 @default.
• W3214747827 hasConceptScore W3214747827C126322002 @default.
• W3214747827 hasConceptScore W3214747827C137403100 @default.
• W3214747827 hasConceptScore W3214747827C143998085 @default.
• W3214747827 hasConceptScore W3214747827C144024400 @default.
• W3214747827 hasConceptScore W3214747827C19165224 @default.
• W3214747827 hasConceptScore W3214747827C2775969662 @default.
• W3214747827 hasConceptScore W3214747827C2776256026 @default.
• W3214747827 hasConceptScore W3214747827C2776530083 @default.

• next